Catalent Stock News

Whittier Trust Co. of Nevada Inc. purchased a new position in shares of Catalent, Inc. (NYSE:CTLT) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 300 shares of the company’s stock, valued at approximately $40,000. Several other institutional investors have also modified […]

The "Pharmaceutical Intermediates" Market report offers qualitative and quantitative insights and a detailed analysis of market size & growth rate for all possible segments in the market. The Global Pharmaceutical Intermediates Industry presents a market overview, product details, classification, and

Catalent, Inc. (NYSE:CTLT) was the recipient of a significant growth in short interest in the month of November. As of November 30th, there was short interest totalling 2,180,000 shares, a growth of 33.7% from the November 15th total of 1,630,000 shares. Based on an average daily volume of 963,300 shares, the days-to-cover ratio is currently []

Catalent, Inc. (NYSE:CTLT) was the recipient of a significant growth in short interest in November. As of November 30th, there was short interest totalling 2,180,000 shares, a growth of 33.7% from the November 15th total of 1,630,000 shares. Currently, 1.3% of the companys shares are sold short. Based on an average trading volume of 963,300 []

Investors continue to be optimistic about Catalent (CTLT) owing to its robust facility expansion activities and a slew of strategic deals.

Investors continue to be optimistic about Catalent (CTLT) owing to its robust facility expansion activities and a slew of strategic deals.

Selective Wealth Management Inc. bought a new stake in Catalent, Inc. (NYSE:CTLT) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 200 shares of the companys stock, valued at approximately $27,000. Other hedge funds have also recently made changes to their positions in []

DUBLIN, Dec. 14, 2021 /PRNewswire/ -- The "Pharmaceutical Analytical Testing Outsourcing Market Research Report by Product Type, Service, End-users, Application, and Region - Global Forecast to 2026 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com''s

Equities analysts expect Catalent, Inc. (NYSE:CTLT) to report earnings of $0.84 per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Catalent’s earnings. The highest EPS estimate is $0.92 and the lowest is $0.77. Catalent reported earnings of $0.63 per share during the same quarter last year, […]

Related Stocks: AMGN , GH , IDXX , ALNY , NVAX , SRPT , ICLR , BHVN , CTLT , CRBU , AZN , RLYB , ABT , ASND , NBIX , DXCM , ARNA , ARGX , DCPH , BBIO , RMD , BPMC , ALLK , IOVA ,

ReportsnReports publishes the report titled Pharmaceutical Intermediates that presents a 360-degree overview of the market under one roof. The report is developed with the meticulous efforts of an enthusiastic and experienced team of experts, analyts, and researchers that makes the

Major players in the single-chamber prefilled syringes market are BD, Gerresheimer, Schott, Catalent, Nipro, Weigao, Stevanato, Baxter, Vetter Pharma, and Terumo. The global single-chamber prefilled syringes market is expected to grow from $4. Major players in the single-chamber prefilled syringes market are BD, Gerresheimer, Schott, Catalent, Nipro, Weigao, Stevanato, Baxter, Vetter Pharma, and Terumo. The global single-chamber prefilled syringes market is expected to grow from $4.

Tran Capital Management L.P. cut its holdings in shares of Catalent, Inc. (NYSE:CTLT) by 29.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 372,491 shares of the companys stock after selling 156,398 shares during the quarter. Catalent comprises approximately 4.2% of Tran []

Key Prominent Players Covered in the CDMO Market are Catalent, Inc , Baxter, Vetter, Recipharm AB, Albany Molecular Research Inc. (AMRI), Thermo Fisher Scientific Inc. (Patheon), Unither, DPT LABORATORIES LTD., NextPharma Technologies, Others. Key Prominent Players Covered in the CDMO Market are Catalent, Inc , Baxter, Vetter, Recipharm AB, Albany Molecular Research Inc. (AMRI), Thermo Fisher Scientific Inc. (Patheon), Unither, DPT LABORATORIES LTD., NextPharma Technologies, Others.

IFP Advisors Inc lessened its holdings in shares of Catalent, Inc. (NYSE:CTLT) by 22.3% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 341 shares of the companys stock after selling 98 shares during the period. IFP Advisors Incs holdings in Catalent were worth $47,000 at []